CTRI/2017/06/008741招募中2 期
â??Bortezomib, Lenalidomide and Dexamethasone based consolidation therapy after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A single arm prospective studyâ??
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All multiple myeloma patients who have undergone Autologous Hematopoietic stem cell transplant will be enrolled at 100 days (± 2weeks) of post ASCT
排除标准
- •1.ECOG Performance status 3 and 4
- •2.Uncontrolled diabetes and hypertension
- •3.peripheral neuropathy > grade 2
- •4.Any contraindication to anticoagulant prophylaxis
- •5.Persistent cytopenias >=1 cell line (Hb < 8 g/dl, Platelets < 1 x 105/cmm, ANC < 1000/cmm)
研究者
相似试验
进行中（未招募）
不适用
Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma - BORID in relapsed mantle cell lymphomarelapsed mantle cell lymphomaEUCTR2004-002150-64-ATMedical University Vienna, Dept. of Medicine I, Clinical Division of Oncology16
进行中（未招募）
不适用
Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma - BVD-CLEM 01-10Relapsed or refractory multiple myelomaMedDRA version: 9.1Level: LLTClassification code 10051381EUCTR2010-020072-33-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
终止
不适用
Bortezomib with lenalidomide and dexamethasone combination as induction therapy in transplantation candidate patients with newly diagnosed multiple myelomaKCT0004005The Catholic University of Korea, Seoul St. Mary's Hospital74
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30
尚未招募
3 期
A comparison of Bortezomib, Pomalidomide with low-dose Dexamethasone and Bortezomib, Lenalidomide with low-dose dexamethasone for newly-diagnosed multiple myeloma patients- A randomized phase III study.CTRI/2019/07/020397Dr Lalit Kumar